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Prediction of Opioid-Induced Respiratory Depression
on Inpatient Wards Using Continuous Capnography
and Oximetry: An International Prospective,
Observational Trial
Ashish K. Khanna, MD,*† Sergio D. Bergese, MD,‡§ Carla R. Jungquist, NP, PhD,‖
Hiroshi Morimatsu, MD, PhD,¶ Shoichi Uezono, MD,# Simon Lee, MD,** Lian Kah Ti, MBBS, MMed,††
Richard D. Urman, MD,‡‡ Robert McIntyre Jr, MD,§§ Carlos Tornero, MD, PhD,‖‖ Albert Dahan, MD, PhD,¶¶
Leif Saager, Dr Med,##*** Toby N. Weingarten, MD,††† Maria Wittmann, MD,‡‡‡ Dennis Auckley, MD,§§§
Luca Brazzi, MD, PhD,‖‖‖ Morgan Le Guen, MD, PhD,¶¶¶ Roy Soto, MD,### Frank Schramm, MD,****
Sabry Ayad, MD,†††† Roop Kaw, MD,†††† Paola Di Stefano, MSc,‡‡‡‡ Daniel I. Sessler, MD,§§§§
Alberto Uribe, MD,‡ Vanessa Moll, MD, PhD,** Susan J. Dempsey, MN,§§‖‖‖‖ Wolfgang Buhre, MD,¶¶¶¶ and
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patients monitored by capnoGraphY (PRODIGY) Group Collaborators
See Articles, p 1007, p 1025, p 1032
BACKGROUND: Opioid-related adverse events are a serious problem in hospitalized patients.
Little is known about patients who are likely to experience opioid-induced respiratory depression
events on the general care floor and may benefit from improved monitoring and early intervention.
The trial objective was to derive and validate a risk prediction tool for respiratory depression in
patients receiving opioids, as detected by continuous pulse oximetry and capnography monitoring.
METHODS: PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) was a prospective, observational trial of blinded continuous capnography
and oximetry conducted at 16 sites in the United States, Europe, and Asia. Vital signs were
intermittently monitored per standard of care. A total of 1335 patients receiving parenteral
opioids and continuously monitored on the general care floor were included in the analysis. A
respiratory depression episode was defined as respiratory rate ≤5 breaths/min (bpm), oxygen
saturation ≤85%, or end-tidal carbon dioxide ≤15 or ≥60 mm Hg for ≥3 minutes; apnea episode
lasting >30 seconds; or any respiratory opioid-related adverse event. A risk prediction tool was
derived using a multivariable logistic regression model of 46 a priori defined risk factors with
stepwise selection and was internally validated by bootstrapping.
RESULTS: One or more respiratory depression episodes were detected in 614 (46%) of 1335
general care floor patients (43% male; mean age, 58 ± 14 years) continuously monitored for
a median of 24 hours (interquartile range [IQR], 17–26). A multivariable respiratory depression prediction model with area under the curve of 0.740 was developed using 5 independent
variables: age ≥60 (in decades), sex, opioid naivety, sleep disorders, and chronic heart failure.
The PRODIGY risk prediction tool showed significant separation between patients with and without respiratory depression (P < .001) and an odds ratio of 6.07 (95% confidence interval [CI],
4.44–8.30; P < .001) between the high- and low-risk groups. Compared to patients without
respiratory depression episodes, mean hospital length of stay was 3 days longer in patients
with ≥1 respiratory depression episode (10.5 ± 10.8 vs 7.7 ± 7.8 days; P < .0001) identified
using continuous oximetry and capnography monitoring.
CONCLUSIONS: A PRODIGY risk prediction model, derived from continuous oximetry and capnography, accurately predicts respiratory depression episodes in patients receiving opioids on the
general care floor. Implementation of the PRODIGY score to determine the need for continuous
monitoring may be a first step to reduce the incidence and consequences of respiratory compromise in patients receiving opioids on the general care floor. (Anesth Analg 2020;131:1012–24)

KEY POINTS
• Question: Can we use continuous capnography and oximetry monitoring data to derive a risk
prediction tool to predict the risk of respiratory depression episodes in patients receiving
parenteral opioid therapy on surgical and medical general care floors?
• Findings: The PRediction of Opioid-induced respiratory Depression In patients monitored by
capnoGraphY (PRODIGY) trial found a 46% incidence of respiratory depression and developed
a novel respiratory depression risk prediction tool, including 5 easy-to-assess variables: age
≥60 years by decade, sex, opioid naivety, sleep disorders, and chronic heart failure.
• Meaning: This risk prediction tool, based on continuous, blinded oximetry and capnography
data, accurately predicts respiratory depression in patients receiving parenteral opioids on the
general care floor.
DOI: 10.1213/ANE.0000000000004788
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GLOSSARY
ASA = American Society of Anesthesiologists; AUC = area under the curve; BMI = body mass
index; bpm = breaths/min; CPAP = continuous positive airway pressure; Etco2 = end-tidal carbon
dioxide; FAS = full analysis set; IPI = Integrated Pulmonary Index; IQR = interquartile range; IRB =
institutional review board; MFAS = modified full analysis set; MME = morphine milligram equivalent; OIRD = opioid-induced respiratory depression; OR = odds ratio; PRODIGY = PRediction of
Opioid-induced respiratory Depression In patients monitored by capnoGraphY; Spo2 = oxygen saturation; STOP = Snoring, Tiredness, Observed apnea, blood Pressure; STROBE = STrengthening the
Reporting of OBservational studies in Epidemiology; STOP-BANG = Snoring, Tiredness, Observed
apnea, blood Pressure, Body mass index, Age, Neck circumference, and Gender

T

he general care floor is a low-acuity inpatient
environment. However, nearly half of all inhospital cardiorespiratory events occur on the
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general care floor, often with catastrophic outcomes.1,2
A national registry identified 44,551 acute respiratory
events in US hospitals, with an associated in-hospital
mortality of nearly 40%.2 Early recognition of respiratory compromise through continuous respiratory
monitoring on the general care floor has been advocated to reduce morbidity and mortality.3,4
Opioid-induced respiratory depression (OIRD)
is one cause of respiratory compromise on the general care floor, in part, because opioid administration remains common practice.5 OIRD is traditionally
defined using surrogate measures, such as hypoventilation with or without oxygen desaturation, and is
often a diagnosis of exclusion.6 Its reported incidence
between 0.3% and 21% is likely an underestimation
of the true incidence.7,8 Opioid-related adverse events,
including OIRD, are associated with increased length
of stay (mean 5 additional days), readmission (15.8%
vs 9.4% in patients without events), and cost (mean
increase $10,000).9 The earliest warning of respiratory
failure due to OIRD may be subtle changes in vital
signs 6–8 hours before critical cardiac and respiratory decompensation ensues.10 Current general care
floor monitoring often misses these early patterns or
infers incorrect patterns, which are key to preventing catastrophic events. One investigation revealed
that intermittent “spot check” monitoring every 4–6
hours missed >90% episodes of prolonged hypoxemia
on the general care floor.7 Similarly, in a closed claims
analysis of the American Society of Anesthesiologists
(ASA), a majority of the >357 OIRD events evolved
rapidly and almost all could have been prevented
with adequate monitoring and timely responses.11 It
remains difficult to predict which general care floor
patients are likely to decompensate when receiving
analgesic opioids.12
The PRediction of Opioid-induced respiratory
Depression In patients monitored by capnoGraphY
(PRODIGY) trial investigated the incidence and risk
factors associated with respiratory depression episodes in hospitalized patients receiving parenteral
opioids and monitored by continuous capnography
and oximetry. A respiratory depression risk prediction
model was derived and validated, and the PRODIGY
risk prediction tool was created.
www.anesthesia-analgesia.org 1013
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METHODS
Trial Design, Setting, and Participants
PRODIGY was a prospective trial conducted at 16
clinical sites in the United States, Europe, and Asia
(Supplemental Digital Content, Table 1, http://links.
lww.com/AA/D71), performed between April 2017
and May 2018 (ClinicalTrials.gov: NCT02811302; registered Study Chair: F.J.O.; registration date: June 2016).
The trial was registered before patient enrollment
and conducted in compliance with the Declaration
of Helsinki and applicable laws and regulations of
participating countries, including institutional review
board (IRB) or Research Ethics Committee approval.
Eligible patients included adults (≥18, 20, and 21
years in United States/Europe, Japan, and Singapore,
respectively) able to provide written informed consent, expected to receive parenteral opioid therapy
on the general care floor, and able to wear continuous monitoring equipment. Exclusion criteria were
previously described (Supplemental Digital Content,
Table 2, http://links.lww.com/AA/D71).1 Patients
receiving opioids for nonsurgical pain were eligible for enrollment in the United States; all patients
enrolled outside the United States were postsurgical.
All adverse events were documented during continuous monitoring and at 30-day follow-up. Respiratory
depression episodes were classified as respiratory
opioid-related adverse events only if standard of care
monitoring indicated the patient was symptomatic of
respiratory depression and intervention was required.
Procedures
Enrolled patients were monitored in adherence to each
sites’ practice (vital sign checks every 4–8 hours), as
well as continuous capnography and pulse oximetry
monitoring, collected with a Capnostream 20p or 35
portable bedside monitor (Medtronic, Boulder, CO).
Continuous monitoring readings, alarms, and data
were blinded to health care providers. Monitoring
began after arrival on the general care floor and initiation of opioid therapy. Supplemental oxygen was
allowed according to each sites’ clinical practice. A
30-day follow-up phone call was conducted. Clinical
sites were limited to maximum 20% of total enrollment.
Trial Objectives
The primary objective was to derive and validate a risk
prediction tool for respiratory depression in patients
receiving opioids, as detected by continuous pulse
oximetry and capnography monitoring (primary end
point). A respiratory depression episode was defined as
any of the following: respiratory rate ≤5 breaths/min
(bpm) for ≥3 minutes, oxygen saturation (Spo2) ≤85%
for ≥3 minutes, end-tidal carbon dioxide (Etco2) ≤15
or ≥60 mm Hg for ≥3 minutes, apnea episode lasting
>30 seconds, or any respiratory opioid-related adverse
1014   
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event (Supplemental Digital Content, Table 3, http://
links.lww.com/AA/D71). The ≥3-minute threshold
was used to minimize technical artifacts and transient
threshold deviations. An independent clinical event
committee reviewed Etco2, Spo2, respiratory rate, and
heart rate tracings and decided on the presence of a
respiratory episode and excluded artifacts on a case-bycase basis using a predefined priority list (Supplemental
Digital Content, Table 4, http://links.lww.com/AA/
D71). To evaluate respiratory depression relatedness
to opioids, the committee had access to time records of
opioid use on the general care floor but was blinded to
all other patient medical and clinical history.
A priori defined secondary objectives included (1)
comparing patients with and without ≥1 respiratory
depression episode, with end points including adverse
event incidence and health care resource utilization
and (2) calculating the predictive value of Etco2, respiratory rate, Spo2, and the Integrated Pulmonary Index
(IPI) algorithm (determined by integrating Etco2,
respiratory rate, Spo2, and heart rate signals into a
single index using fuzzy logic)13 on the occurrence of
respiratory depression for patients with ≥1 adjudicated
respiratory depression episode, using sensitivity and
specificity measures. Primary and secondary objectives used a modified full analysis set, including only
enrolled patients who started continuous monitoring
and received parenteral opioid therapy, because some
patients were enrolled based on “planned” opioid
administration but did not receive opioids. Patients
with only respiratory opioid-related adverse events
occurring outside of continuous monitoring were
excluded from the modified full analysis set.
Sample Size Calculations
A total of 1650 patients were calculated as adequate,
based on expected model derivation with 12 predictors, and a combined 12% reported incidence of respiratory rate ≤8 bpm, Spo2 ≤85%, or Etco2 ≥60 mm Hg,
each for ≥3 minutes.1,7,14 Enrollment was monitored
and ended with 1495 patients due to high prevalence
(44%) of adjudicated respiratory depression episodes;
this was sufficient to power statistical analysis.
Statistical Analysis
Descriptive statistics were used to summarize patient
characteristics, including mean, standard deviation,
median, minimum, maximum, and interquartile
range (IQR) for continuous variables, and counts and
percentages for categorical variables. To compare
patients with and without respiratory depression episodes, categorical variables were analyzed with the χ2
test or the Fisher exact test, and continuous variable
parameter comparisons were performed using t test
or Wilcoxon test, as appropriate. Statistical tests used
a 2-sided significance level of .05. All data analysis
ANESTHESIA & ANALGESIA
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used SAS v9.4 (SAS Institute Inc, Cary, NC). This manuscript adheres to the applicable STrengthening the
Reporting of OBservational studies in Epidemiology
(STROBE) guidelines.
Risk Prediction Derivation
Medical and clinical information were collected at
patient enrollment or during continuous monitoring
through medical chart review; adverse events, protocol deviations, and health care resource utilization
information were collected during 30-day follow-up.
Due to low prevalence of some risk factors and the
unexpected high respiratory depression occurrence,
the risk prediction tool was derived using all patients,
instead of the derivation–validation split defined in
the published trial protocol.1
Forty-six a priori defined variables collected during
the trial were assessed, including 12 variables previously described as respiratory depression risk factors
(Supplemental Digital Content, Table 5, http://links.
lww.com/AA/D71).3,15–19 Opioid naivety was defined
as no history of opioid use as documented in available
health records. Known or suspected sleep-disordered
breathing included medical history of obstructive sleep
apnea, the use of continuous positive airway pressure
(CPAP), or confirmation of the Snoring, Tiredness,
Observed apnea, blood Pressure (STOP) questions in
the Snoring, Tiredness, Observed apnea, blood Pressure,
Body mass index, Age, Neck circumference, and Gender
(STOP-BANG) questionnaire. Variable collinearity was
tested by Spearman rho, where a correlation coefficient >0.25 was used to identify covariables, and clinical judgment used to determine covariable exclusion.20
Covariables with prevalence <0.5% or >90% were also
excluded, resulting in 31 variables (Supplemental Digital
Content, Table 5, http://links.lww.com/AA/D71).
Bivariable odds ratios (ORs) and 95% confidence
intervals (95% CIs) were estimated for all 31 variables.
The multivariable logistic regression model used stepwise selection with entry 0.25, stay criteria 0.15, and
respiratory depression as the dependent variable. The
model included all 2 × 2 interactions, with geography
and effective length of monitoring (in quartiles, calculated as the total length of capnography monitoring
excluding temporary gaps in monitoring) as random
effects due to a correlation between monitoring length
and respiratory depression occurrence. The main accuracy measure was the C-statistic equal to the area under
the curve (AUC), derived from the mixed model. The
final model was assessed using the calibration plot
(predicted probability in deciles). Model prediction performance was assessed using R2, Somers D, γ, τ-a, and
Brier score. Internal model validation was assessed by
bootstrapping with stepwise variable selection, estimating the optimism (500 random samples with replacement from the original dataset), as recommended in
October 2020 • Volume 131 • Number 4

the literature.21–23 The adjusted AUC was the difference between the AUC and optimism. Five-fold crossvalidation with 10 replicates, for a total of 50 iterations,
was performed to confirm bootstrapping results. Crossvalidation was also performed using each trial site as a
test set to confirm model performance across different
hospital settings.24 The cross-validation performances
were reported as the average AUC along with bias as
the difference between the apparent and the test.
Risk Score Development
The PRODIGY risk score was calculated by multiplying each β coefficient by 10, rounding to the nearest
integer, and adding all integers. The resulting continuous distribution of risk scores was stratified into 3 categories according to the risk level (tertiles), as planned
before trial onset. The risk tool was assessed for accuracy using sensitivity and specificity, and respiratory
depression incidence by risk levels was determined.
Missing Data
Because the clinical event committee adjudicated
the respiratory depression episodes, there were no
missing respiratory depression data. No imputation
was used because missing covariable data were sufficiently low (5.2%), given that a 10% cutoff is typical
for large samples and no established cutoff defining
an acceptable percentage of missing data exists.25
RESULTS
Patient Characteristics and Prevalence of
Respiratory Depression
In total, 1495 patients were enrolled, with 114 patients
excluded due to major protocol deviations; 1282 patients
completed 30-day follow-up (Figure). The median
effective monitoring time was 24 hours (IQR, 17–26) for
1335 monitored patients (Figure; Supplemental Digital
Content, Figure 1, http://links.lww.com/AA/D71).
Median morphine milligram equivalents (MMEs) on
the general care floor were 15 MMEs (IQR, 3–52) and
20 MMEs (IQR, 5–60) for patients with ≥1 or without
respiratory depression episodes, respectively. The clinical event committee adjudicated 5768 potential respiratory depression episodes in 1347 patients, including
some patients who did not receive parenteral opioids
(Supplemental Digital Content, Figure 2, http://links.
lww.com/AA/D71). Of all enrolled patients, 655 (44%
of the full analysis set) were adjudicated as having at
least 1 respiratory depression episode during the monitoring period, including 614 patients who received
opioids and started continuous monitoring (46% of the
modified full analysis set). Baseline characteristics varied by location, with US sites enrolling younger patients
with a higher body mass index (BMI, ≥35 kg/m2),
larger neck circumference, higher ASA physical status,
and higher STOP-BANG score, compared to patients
www.anesthesia-analgesia.org 1015
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Figure. STROBE diagram detailing patient
disposition throughout the trial, including patients in the FAS and the MFAS.
a
Including 12-h nocturnal monitoring up
to 2 consecutive nights (when possible).
FAS indicates full analysis set; Incl/Excl,
Inclusion/Exclusion; MFAS, modified full
analysis set; STROBE, STrengthening the
Reporting of OBservational studies in
Epidemiology.

enrolled in Europe or Asia (Table 1). Of the 1185 patients
who had ≥1 potential respiratory depression episode,
731 patients (62%) received supplemental oxygen during monitoring. A significantly higher percentage of
patients enrolled in Asia were opioid naive (Table 1).
Univariable Predictors of Respiratory Depression
Significant univariable respiratory depression predictors included age ≥70 to <80 or ≥80 years, male sex,
BMI ≥20 to <25 or ≥35 kg/m2, opioid naivety, administration of ≥1 to <4 opioids, chronic heart failure, coronary artery disease, hypertension, type II diabetes,
kidney failure, and asthma (Table 2).
Respiratory Depression Risk Assessment Tool
The multivariable model for respiratory depression
prediction was developed using 1266 patients (69
missing data) and included 5 independent variables:
age ≥60 to <70 years (OR, 2.24 [95% CI, 1.69–2.99]; P <
.0001), ≥70 to <80 years (OR, 3.43 [95% CI, 2.41–4.89];
P < .0001), and ≥80 years (OR, 4.78 [95% CI, 2.33–9.80];
P < .0001); male sex (OR, 2.13 [95% CI, 1.65–2.74]; P
< .0001); opioid naivety (OR, 1.34 [95% CI, 0.97–1.85];
P = .078); sleep disorders (known or suspected sleep
1016   
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disorders, including obstructive sleep apnea; OR, 1.61
[95% CI, 1.10–2.38]; P = .018); and chronic heart failure
(OR, 2.12 [95% CI, 0.95–4.72]; P = .067) (Table 3). This
multivariable model had an AUC of 0.76 (95% CI, 0.73–
0.79) and a Hosmer–Lemeshow goodness-of-fit statistic test with P = .831 (Supplemental Digital Content,
Figure 3, http://links.lww.com/AA/D71). The
adjusted AUC was 0.7406, considering the low optimism (0.020). Bootstrapping selected the final model
variables, including age, male sex, opioid naivety,
sleep disorders, and chronic heart failure in 89%, 89%,
24%, 31%, and 37% of 500 replicates, respectively
(Supplemental Digital Content, Table 6, http://links.
lww.com/AA/D71). Complementary statistics comparing the fitted model with the null model included
Brier score 0.19 (range for perfect model to null model,
0–0.25), scaled Brier score 22% (range, 0–100), R2 0.22
(range, 0–1), and adjusted R2 0.29 (range, 0–1).24 Rank
correlation indexes measuring the ordinal association
between 2 variables included Somers D 0.52, γ 0.53,
and τ-a 0.26 (all on a −1 to 1 scale).24 Five-fold crossvalidation of the multivariable model resulted in an
average AUC of 0.78 with bias equal to −0.02; similar results were observed using cross-validation by
ANESTHESIA & ANALGESIA
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Table 1.  Patient Demographics and Baseline Characteristics
Clinical Characteristics
Age (y)
Mean ± SD
Median (IQR)
Age (y) classes
<60
≥60 to <70
≥70 to <80
≥80
Sex (male)
BMI (kg/m2)
Mean ± SD
Median (IQR)
BMI (kg/m2)
<20
≥20 to <25
≥25 to <30
≥30 to <35
≥35
Race/ethnicity
American Indian or Alaska Native
Asian
Black or African American
Hispanic or Latino
Native Hawaiian or Other Pacific
White
Other
Current smoker
Neck circumference (≥17 in M; ≥16 in F)
ASA physical status
I
II
III
IV
Surgery demographics
Surgical patient
High-risk surgeryb
Open surgery
Length of surgery (h)
<2
≥2 to <4
≥4
Opioid demographics
Opioid epidural and IV route
Opioid Naivec
Multiple opioids or concurrent CNS/
sedating medication
No. of distinct opioids
1 opioid
Opioid number >1 to <4
Opioid number ≥4
Cardiac disorders
Aortic aneurysm
Aortic valve disease
CHF
Coronary artery disease
Hypertension
Mitral valve disease
Myocardial infarction
Orthostatic hypotension
Pulmonary hypertension
Hepatobiliary disorders
Liver failure
Immune disorders
Sarcoidosis

United States
(n = 769)

Europe
(n = 254)

Asia
(n = 312)

Total
(n = 1335)

Significance
(P)a

54.9 ± 14.7
56.0 (44.0–65.0)

60.2 ± 12.5
61.5 (53.0–69.0)

62.7 ± 12.4
65.0 (57.0–70.0)

57.7 ± 14.2
59.0 (49.0–68.0)

<.001

252/769 (32.8)
184/769 (23.9)
103/769 (13.4)
24/769 (3.1)
287/769 (37.3)

42/254 (16.5)
86/254 (33.9)
46/254 (18.1)
12/254 (4.7)
126/254 (49.6)

35/312 (11.2)
122/312 (39.1)
75/312 (24.0)
13/312 (4.2)
157/312 (50.3)

329/1335 (24.6)
392/1335 (29.4)
224/1335 (16.8)
49/1335 (3.7)
570/1335 (42.7)

<.001

32.0 ± 9.2
30.1 (25.5–36.8)

27.8 ± 6.5
26.7 (23.3–30.7)

25.0 ± 4.5
24.5 (21.9–27.6)

29.6 ± 8.4
27.8 (23.7–33.3)

<.001

31/769 (4.0)
143/769 (18.6)
208/769 (27.0)
146/769 (19.0)
241/769 (31.3)

10/252 (4.0)
89/252 (35.3)
83/252 (32.9)
44/252 (17.5)
26/252 (10.3)

36/312 (11.5)
138/312 (44.2)
95/312 (30.4)
35/312 (11.2)
8/312 (2.6)

77/1333 (5.8)
370/1333 (27.7)
386/1333 (29.0)
225/1333 (16.9)
275/1333 (20.6)

<.001

3/769 (0.4)
6/769 (0.8)
157/769 (20.4)
9/769 (1.2)
1/769 (0.1)
586/769 (76.2)
7/769 (0.9)
120/769 (15.6)
351/766 (45.8)

0/254 (0)
2/254 (0.8)
1/254 (0.4)
0/254 (0)
0/254 (0)
148/254 (58.3)
21/254 (8.3)
49/254 (19.3)
51/205 (24.9)

1/312 (0.3)
309/312 (99.0)
0/312 (0)
0/312 (0)
0/312 (0)
2/312 (0.6)
0/312 (0)
30/312 (9.6)
17/312 (5.4)

4/1335 (0.3)
317/1335 (23.7)
158/1335 (11.8)
9/1335 (0.7)
1/1335 (0.1)
736/1335 (55.1)
28/1335 (2.1)
199/1335 (14.9)
419/1283 (32.7)

<.001

4/744 (0.5)
266/744 (35.8)
448/744 (60.2)
26/744 (3.5)

35/254 (13.8)
152/254 (59.8)
66/254 (26.0)
1/254 (0.4)

75/312 (24.0)
206/312 (66.0)
31/312 (9.9)
0/312 (0.0)

114/1310 (8.7)
624/1310 (47.6)
545/1310 (41.6)
27/1310 (2.1)

<.001

693/769 (90.1)
39/769 (5.1)
50/769 (6.5)

254/254 (100.0)
25/254 (9.8)
21/254 (8.3)

312/312 (100.0)
18/312 (5.8)
1/312 (0.3)

1259/1335 (94.3)
82/1335 (6.1)
72/1335 (5.4)

<.001
.022
<.001

290/769 (37.7)
311/769 (40.4)
168/769 (21.8)

53/254 (20.9)
125/254 (49.2)
76/254 (29.9)

87/312 (27.9)
119/312 (38.1)
106/312 (34.0)

430/1335 (32.2)
555/1335 (41.6)
350/1335 (26.2)

<.001

133/1335 (10.0)
(80.6) 1076/1335
(93.5) 1248/1335

<.001
<.001
<.001

32/769 (4.2)
551/769 (71.7)
722/769 (93.9)

8/254 (3.1)
224/254 (88.2)
220/254 (86.6)

93/312 (29.8)
301/312 (96.5)
306/312 (98.1)

<.001

.004
<.001

69/769 (9.0)
451/769 (58.6)
249/769 (32.4)

52/254 (20.5)
152/254 (59.8)
50/254 (19.7)

8/312 (2.6)
277/312 (88.8)
27/312 (8.7)

129/1335 (9.7)
880/1335 (65.9)
326/1335 (24.4)

<.001
<.001

8/769 (1.0)
12/769 (1.6)
26/768 (3.4)
55/767 (7.2)
366/769 (47.6)
13/769 (1.7)
21/768 (2.7)
3/769 (0.4)
8/769 (1.0)

2/254 (0.8)
4/254 (1.6)
7/254 (2.8)
10/254 (3.9)
96/254 (37.8)
6/254 (2.4)
9/254 (3.5)
1/254 (0.4)
1/254 (0.4)

0/312 (0)
2/312 (0.6)
2/312 (0.6)
16/312 (5.1)
150/312 (48.1)
1/312 (0.3)
4/312 (1.3)
0/312 (0)
0/312 (0)

10/1335 (0.7)
18/1335 (1.3)
35/1334 (2.6)
81/1333 (6.1)
612/1335 (45.8)
20/1335 (1.5)
34/1334 (2.5)
4/1335 (0.3)
9/1335 (0.7)

.200
.487
.023
.126
.017
.110
.209
.644
.124

10/1335 (0.7)

.011

3/1335 (0.2)

.767

2/769 (0.3)

2/254 (0.8)

6/312 (1.9)

3/769 (0.4)

0/254 (0)

0/312 (0)

(Continued)
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Table 1.  Continued
Clinical Characteristics
Infections
Multiple organ dysfunction syndrome
Sepsis
Metabolism and nutrition disorders
Diabetes—type I
Diabetes—type II
Musculoskeletal and connective tissue disorders
Muscular dystrophy
Amyotrophic lateral sclerosis
Renal and urinary disorders
Kidney failure
Respiratory, thoracic, and mediastinal disorders
Acute bronchitis
Asthma
Chronic bronchitis
Chronic obstructive pulmonary disease
Chronic restrictive lung disease
Cystic fibrosis
Emphysema
Pneumonia
Pulmonary fibrosis
Sleep disordersd
Vascular disorders
Cerebral aneurysm
Peripheral vascular disease
Stroke
Transient ischemic attack
STOP-BANG score class
Low risk (0–2)
Intermediate risk (3–4)
High risk (5–8)

United States
(n = 769)

Europe
(n = 254)

2/769 (0.3)
15/769 (2.0)

0/254 (0)
2/254 (0.8)

18/769 (2.3)
124/769 (16.1)

1/254 (0.4)
37/254 (14.6)

Total
(n = 1335)

Significance
(P)a

0/312 (0)
0/312 (0)

2/1335 (0.1)
17/1335 (1.3)

1.000
.014

0/312 (0)
53/312 (17)

19/1335 (1.4)
214/1335 (16.0)

.002
.733

0/254 (0)
0/254 (0)

0/312 (0)
0/312 (0)

2/1335 (0.1)
0/1335 (0)

1.000
1.000

29/769 (3.8)

14/254 (5.5)

11/312 (3.5)

54/1335 (4.0)

.412

13/769 (1.7)
121/769 (15.7)
9/769 (1.2)
60/769 (7.8)
3/769 (0.4)
0/769 (0)
5/769 (0.7)
15/769 (2.0)
2/769 (0.3)
127/760 (16.7)

0/254 (0)
18/254 (7.1)
3/254 (1.2)
12/254 (4.7)
0/254 (0)
0/254 (0)
0/254 (0)
6/254 (2.4)
0/254 (0)
13/195 (6.7)

0/312 (0)
23/312 (7.4)
1/312 (0.3)
7/312 (2.2)
0/312 (0)
0/312 (0)
0/312 (0)
9/312 (2.9)
0/312 (0)
7/312 (2.2)

13/1335 (1.0)
162/1335 (12.1)
13/1335 (1.0)
79/1335 (5.9)
3/1335 (0.2)
0/1335 (0)
5/1335 (0.4)
30/1335 (2.2)
2/1335 (0.1)
147/1267 (11.6)

0/254 (0)
8/254 (3.1)
5/254 (2.0)
4/254 (1.6)

0/312 (0)
2/312 (0.6)
5/312 (1.6)
2/312 (0.6)

2/769 (0.3)
0/769 (0)

8/769 (1.0)
18/769 (2.3)
14/768 (1.8)
11/768 (1.4)
343/756 (45.4)
265/756 (35.1)
148/756 (19.6)

102/192 (53.1)
60/192 (31.3)
30/192 (15.6)

Asia
(n = 312)

180/312 (57.5)
114/312 (36.5)
18/312 (5.8)

8/1335 (0.6)
28/1335 (2.1)
24/1334 (1.8)
17/1334 (1.3)
625/1260 (49.6)
439/1260 (34.8)
196/1260 (15.6)

.006
<.001
.402
.001
.767
.767
.234
.638
1.000
<.001
.066
.090
.946
.561
<.001

Medical patients were enrolled at US sites only, and medical history was collected from chart review.
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CHF, chronic heart failure; CNS, central nervous system; CPAP, continuous
positive airway pressure; ESC/ESA, European Society of Cardiology/European Society of Anaesthesiology; F, female; IQR, interquartile range; IV, intravenous; M,
male; SD, standard deviation; STOP, Snoring, Tiredness, Observed apnea, blood Pressure; STOP-BANG, Snoring, Tiredness, Observed apnea, blood Pressure, Body
mass index, Age, Neck circumference, and Gender.
a
P values are not adjusted for multiple comparisons.
b
High-risk surgery was defined using the revised ESC/ESA guidelines on noncardiac surgery.
c
Opioid naive was defined as no use of any opioids in patient medication history.
d
Sleep disorders included medical history of obstructive sleep apnea, use of CPAP, or confirmation of the STOP questions in the STOP-BANG questionnaire.

trial site, where the average AUC was 0.83 and bias
equaled −0.06.
The PRODIGY score equaled the sum of points for
each predictor, and score distribution was divided into
low-, intermediate-, and high-risk tertiles (Table 3).
The average predicted probability for a PRODIGY
score <8, ≥8 to <15, and ≥15 was 0.18–0.39, 0.33–0.65,
and 0.50–0.89, respectively. Within the PRODIGY
score high-risk group, 65% of patients had ≥1 respiratory depression episode, compared to 42% and 24%
of patients in the intermediate- and low-risk groups
(Table 3). Patients with or without respiratory depression had significant separation in PRODIGY scores
(P < .001) (Supplemental Digital Content, Figure 4,
http://links.lww.com/AA/D71). High- and intermediate-risk scores had positive and negative predictive
values equal to 0.65 and 0.54 and 0.66 and 0.76, respectively. The high- and low-risk groups had OR of 6.07
(95% CI, 4.44–8.30; P < .001) (Table 3), with high sensitivity and specificity for the intermediate- (≥8 points)
and high-risk (≥15 points) groups, respectively.
1018   
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Predictive Value of Continuous Monitoring
Parameters
The most common capnography and pulse oximetry
alarms were for apnea, low respiratory rate, and low
Etco2, with adjudicated respiratory depression episodes occurring in 596, 155, and 141 patients, respectively (Table 4). No high Etco2 cases were observed.
IPI <5 (1–10 scale with lower numbers indicating
worse status) and apnea had the highest sensitivity
(97.16; 95% CI, 95.84–98.16 and 95.01; 95% CI, 93.35–
96.35, respectively), and low Spo2 with low Etco2 had
the highest specificity (98.75; 95% CI, 98.36–99.06) in
detecting respiratory depression episodes (Table 4).
Adverse Events and Health Care Resource Utilization
A total of 313 patients experienced ≥1 adverse event,
including 22 opioid-related adverse events in 18
patients (Supplemental Digital Content, Table 7,
http://links.lww.com/AA/D71). Ten opioid-related
adverse events were detected by capnography
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Table 2.  Univariable Predictors of Respiratory Depression
Clinical Characteristics
Age (y)
<60
≥60 to <70
≥70 to <80
≥80
Sex (male)
BMI (kg/m2)
<20
≥20 to <25
≥25 to <30
≥30 to <35
≥35
Current smoker
Sleep disorders
Cardiac disorders
Aortic aneurysm
Aortic valve disease
CHF
Coronary artery disease
Hypertension
Mitral valve disease
Myocardial infarction
Pulmonary hypertension
Hepatobiliary disorders
Liver failure
Infections
Sepsis
Metabolism and nutrition disorders
Diabetes—type I
Diabetes—type II
Renal and urinary disorders
Kidney failure
Respiratory, thoracic, and mediastinal disorders
Acute bronchitis
Asthma
Chronic bronchitis
Chronic obstructive pulmonary disease
Vascular disorders
Cerebral aneurysm
Peripheral vascular disease
Stroke
Transient ischemic attack
Surgery information
High-risk surgery
Open surgery
Length of surgery (h)
<2
≥2 to <4
≥4
No. of distinct opioids
Opioid naive
One opioid
Opioid number ≥1 to <4
Opioid number ≥4

Patients With ≥1
Respiratory Depression
Episode (n = 614), n/N (%)

Patients Without
Respiratory Depression
(n = 721), n/N (%)

73/614 (11.9)
213/614 (34.7)
149/614 (24.3)
34/614 (5.5)
327/614 (53.3)

256/721 (35.5)
179/721 (24.8)
75/721 (10.4)
15/721 (2.1)
243/721 (33.7)

2.47
4.12
4.70
2.24

…
(1.91–3.19)
(2.99–5.68)
(2.51–8.81)
(1.80–2.80)

…
.585
<.001
.014
<.001

34/612 (5.6)
188/612 (30.7)
186/612 (30.4)
112/612 (18.3)
92/612 (15.0)
90/614 (14.7)
75/575 (13.0)

43/721 (6.0)
182/721 (25.2)
200/721 (27.7)
113/721 (15.7)
183/721 (25.4)
109/721 (15.1)
72/692 (10.4)

1.31
1.18
1.25
0.64
0.96
1.29

…
(0.80–2.14)
(0.72–1.92)
(0.75–2.11)
(0.38–1.06)
(0.71–1.31)
(0.92–1.82)

…
.029
.236
.130
<.001
.814
.145

8/614 (1.3)
12/614 (2.0)
24/613 (3.9)
47/612 (7.7)
321/614 (52.3)
9/614 (1.5)
20/613 (3.3)
5/614 (0.8)

2/721 (0.3)
6/721 (0.8)
11/721 (1.5)
34/721 (4.7)
291/721 (40.4)
11/721 (1.5)
14/721 (1.9)
4/721 (0.6)

4.75
2.38
2.63
1.68
1.62
0.96
1.70
1.47

(1.00–22.43)
(0.89–6.37)
(1.28–5.41)
(1.07–2.65)
(1.30–2.01)
(0.40–2.33)
(0.85–3.40)
(0.39–5.51)

.049
.085
.009
.025
<.001
.929
.132
.565

6/614 (1.0)

4/721 (0.6)

1.77 (0.50–6.30)

.379

9/614 (1.5)

8/721 (1.1)

1.33 (0.51–3.46)

.562

9/614 (1.5)
112/614 (18.2)

10/721 (1.4)
102/721 (14.1)

1.06 (0.43–2.62)
1.35 (1.01–1.81)

.903
.043

33/614 (5.4)

21/721 (2.9)

1.89 (1.08–3.31)

.025

4/614 (0.7)
55/614 (9.0)
7/614 (1.1)
43/614 (7.0)

9/721 (1.2)
107/721 (14.8)
6/721 (0.8)
36/721 (5.0)

0.52
0.56
1.38
1.43

(0.16–1.69)
(0.40–0.80)
(0.46–4.12)
(0.91–2.26)

.277
.001
.568
.122

1.96
1.58
1.40
1.69

(0.47–8.26)
(0.74–3.37)
(0.62–3.14)
(0.64–4.47)

.356
.235
.417
.290

Significance
(P)

5/614 (0.8)
16/614 (2.6)
13/613 (2.1)
10/613 (1.6)

3/721
12/721
11/721
7/721

41/614 (6.7)
34/614 (5.5)

41/721 (5.7)
38/721 (5.3)

1.19 (0.76–1.86)
1.05 (0.65–1.70)

.453
.829

184/614 (30.0)
264/614 (43.0)
166/614 (27.0)

246/721 (34.1)
291/721 (40.4)
184/721 (25.5)

…
1.21 (0.94–1.56)
1.21 (0.91–1.60)

…
.374
.467

520/614
55/614
431/614
128/614

556/721 (77.1)
74/721 (10.3)
449/721 (62.3)
198/721 (27.5)

1.64 (1.24–2.17)
…
1.29 (0.89–1.88)
0.87 (0.58–1.32)

<.001
…
.009
.071

(84.7)
(9.0)
(70.2)
(20.8)

(0.4)
(1.7)
(1.5)
(1.0)

OR (95% CI)

Abbreviations: BMI, body mass index; CHF, chronic heart failure; CI, confidence interval; OR, odds ratio.

and pulse oximetry monitoring; 11 occurred in
the absence of continuous monitoring and were
excluded during model derivation (Supplemental
Digital Content, Table 8, http://links.lww.com/AA/
D71). Of patients with opioid-related adverse events,
9, 6, and 3 were high-, intermediate-, and low-risk
on the PRODIGY score, respectively. Patients with
October 2020 • Volume 131 • Number 4

≥1 respiratory depression episode (N = 655) were
more likely to experience an adverse event that
required action, with a relative risk of 1.36 (95% CI,
1.01–1.78; P = .040) for adverse events requiring prolonged hospitalization and 2.46 (95% CI, 1.73–3.50; P
< .001) for adverse events requiring rescue, including rapid response team activation, versus patients
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Table 3.  Multivariable Model Prediction of Respiratory Depression, PRODIGY Scoring System, and Utilization
Clinical Characteristic
Age (y)
<60
≥60 to <70
≥70 to <80
≥80
Sex (M)
Opioid naive
Sleep disorders
Chronic heart failure

Multivariable Model Predictors
Estimate
Standard Error
Reference
0.8077
1.2323
1.5647
0.7550
0.2912
0.4755
0.7494

…
0.1458
0.1805
0.3657
0.1284
0.1652
0.1998
0.4085

PRODIGY Score Distribution
Low Risk
Intermediate Risk
PRODIGY score
% Pts with respiratory depression in
risk category (n Pts in risk category
with respiratory depression/n Pts in
risk category)
Sensitivity (95% CI)
Specificity (95% CI)
PPV (95% CI)
NPV (95% CI)
OR (95% CI; P)

<8 points
24% (83/351)

…
…
…
…
ORIL =2.34
(1.72–3.19; P < .001)
ORHL = 6.07
(4.44–8.30; P < .001)

OR (95% CI)

Pr > |t|

…
2.243 (1.685–2.985)
3.429 (2.407–4.886)
4.781 (2.333–9.798)
2.128 (1.654–2.737)
1.338 (0.968–1.850)
1.609 (1.087–2.381)
2.116 (0.949–4.715)

…
<0.0001
<0.0001
<0.0001
<0.0001
0.0782
0.0175
0.0668

High Risk

P

≥8 and <15 points
42% (192/457)

≥15 points
65% (299/458)

<.0001

0.86 (0.82–0.88)
0.39 (0.35–0.42)
0.54 (0.50–0.57)
0.76 (0.72–0.81)
ORHI =2.6
(1.99–3.39; P < .001)

0.52
0.77
0.65
0.66

Points if Clinical
Characteristic = “Yes”
0
8
12
16
8
3
5
7
“Sum = PRODIGY Score”

(0.48–0.56)
(0.74–0.80)
(0.61–0.70)
(0.63–0.69)

Abbreviations: CI, confidence interval; M, male; NPV, negative predictive value; OR, odds ratio; ORHI, odds ratio, high- versus intermediate-risk groups; ORHL, odds
ratio, high- versus low-risk groups; ORIL, odds ratio, intermediate- versus low-risk groups; PPV, positive predictive value; PRODIGY, PRediction of Opioid-induced
respiratory Depression In patients monitored by capnoGraphY; Pts, patients.

without respiratory depression (Supplemental
Digital Content, Table 9, http://links.lww.com/
AA/D71). Of 46 adverse events with rescue action,
30 occurred in patients with ≥1 respiratory depression episode. Readmission (≤30 days) did not differ
significantly between patients with or without respiratory depression. Mean hospital length of stay was
3 days longer in patients with ≥1 respiratory depression episode (10.5 ± 10.8 vs 7.7 ± 7.8 days; P < .0001;
Supplemental Digital Content, Table 10, http://
links.lww.com/AA/D71).
DISCUSSION
Despite its commonality on the general care floor,
predicting respiratory depression remains challenging.12 Multiple prediction scores have been developed
using postoperative pulmonary complications.26,27
The PRODIGY trial is novel because it derived a
respiratory depression risk prediction tool using continuously monitored oximetry and capnography data,
which were prospectively collected and evaluated
using independent expert waveform verification.
The PRODIGY risk prediction tool performed similarly when validated by bootstrapping and by crossvalidation (adjusted AUC, 0.74 and 0.76, respectively),
confirming that the model performs well overall and
across 16 individual trial sites. Prediction models for
postoperative pulmonary complications have reported
adjusted AUCs between 0.72 and 0.82,15,28–30 with one
1020   
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model reaching 0.88.26 The PRODIGY risk score compares well and is distinct from other prediction models, which are derived using intermittent vital signs or
continuous pulse oximetry alone. The PRODIGY score
identified 74% of patients with respiratory depression,
with significant separation among low-, intermediate-,
and high-risk groups. The 5 PRODIGY score variables
are simple to assess, making the risk prediction tool
easy to implement. Increasing age >60 years conferred
the highest risk for respiratory depression. Age is a
feature of other respiratory depression risk prediction models,26,27,31 and age-related changes in respiratory physiology and altered opioid pharmacokinetics
could contribute to this observation.32
Postoperative hypoxemia (low Spo2) has been
reported in 21% of postsurgical patients.7 While the
PRODIGY trial saw a higher overall incidence of
respiratory depression (46%), this could be attributed
to the use of multiparameter continuous monitoring (Etco2, Spo2, respiratory rate, and heart rate). A
majority of our patients used supplemental oxygen,
translating into fewer (8%) hypoxemia episodes and
more capnography-detected apneic and hypoventilation episodes.33 As expected, the combination of
hypoventilation and hypoxemia was most specific
for respiratory depression. In contrast to continuous
oximetry and capnography monitoring, intermittent oximetry alone substantially underestimates
respiratory depression incidence, missing >90% of
ANESTHESIA & ANALGESIA
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Table 4.  Predictive Value of Etco2, Respiratory Rate, Spo2, Apnea, and IPI in Predicting Respiratory OpioidRelated Adverse Events

Parameter
High Etco2
Low Etco2
Low respiratory
rate
Low Spo2
Apnea
IPI
IPI <3
IPI <4
IPI <5
Low Etco2 and low respiratory rate
Any alarm (excluding IPI)
High Etco2 and low respiratory rate
High Etco2 and low Spo2
Low Etco2 and low Spo2

Pts With
Device
Episodes,
n/N (%)
0/1185
(0.00)
748/1185
(63.12)
685/1185
(57.81)
155/1185
(13.08)
1150/1185
(97.05)

Pts With
Respiratory
Depressiona
and Device
Episodes, n/N (%)
0/614b
(0.00)
141/614
(22.96)
154/614
(25.08)
48/614
(7.82)
596/614
(97.07)

1169/1185
(98.65)
1169/1185
(98.65)
1179/1185
(99.49)
615/1185
(51.90)
1183/1185
(99.83)
0/1185
(0.00)
0/1185
(0.00)
61/1185
(5.15)

602/614
(98.05)
602/614
(98.05)
604/614
(98.37)
112/614
(18.24)
613/614
(99.84)
0/614
(0.00)
0/614
(0.00)
20/614
(3.26)

Sensitivity %
(95% CI)
...

Specificity %
(95% CI)
...

Positive
Predictive
Value %
(95% CI)
...

Negative
Predictive
Value %
(95% CI)
...

18.73
(16.20–21.46)
22.13
(19.43–25.02)
6.13
(4.64–7.92)
95.01
(93.35–96.35)

57.07
(55.55–58.58)
68.06
(66.61–69.47)
94.00
(93.24–94.70)
13.76
(12.72–14.84)

8.47
(7.28–9.80)
12.82
(11.18–14.61)
17.82
(13.68–22.60)
18.95
(17.80–20.14)

76.79
(75.26–78.27)
80.46
(79.11–81.76)
82.51
(81.40–83.59)
92.85
(90.51–94.75)

96.25
(94.78–97.41)
96.48
(95.04–97.60)
97.16
(95.84–98.16)
14.30
(12.06–16.79)
99.55
(98.84–99.88)
...

6.65
(5.91–7.45)
6.60
(5.86–7.40)
0.84
(0.59–1.17)
72.27
(70.88–73.63)
0.58
(0.37–0.86)
...

17.95
(16.87–19.08)
17.98
(16.90–19.11)
17.22
(16.18–18.29)
9.87
(8.29–11.64)
17.53
(16.48–18.61)
...

89.32
(85.33–92.53)
89.84
(85.88–92.99)
58.33
(44.88–70.93)
79.89
(78.58–81.17)
85.71
(67.33–95.97)
...

...

...

...

...

2.50
(1.57–3.76)

98.75
(98.36–99.06)

29.73
(19.66–41.48)

82.67
(81.59–83.72)

Of the 1185 patients with device episodes, 731 patients received supplemental oxygen during monitoring, with 203 receiving supplemental oxygen at baseline.
Abbreviations: bpm, breaths/min; CI, confidence interval; Etco2, end-tidal carbon dioxide; IPI, Integrated Pulmonary Index; Pts, patients; Spo2, oxygen saturation.
a
Respiratory depression is defined as respiratory rate ≤5 bpm, Spo2 ≤85%, or Etco2 ≤15 or ≥60 mm Hg for ≥3 minutes; apnea episode lasting >30 seconds; or
any respiratory opioid-related adverse event.
b
Patients with potential opioid-related adverse events only were excluded due to the lack of device monitoring.

hypoxemia episodes lasting >1 hour.7,33,34 PRODIGY
observed no instances of high Etco2, which manifests
during slowly developing respiratory depression. In
cases of rapid cessation of breathing, as is typical in
patients with sleep-disordered breathing, Etco2 levels tend to be low.35 This suggests that most OIRD
developed rapidly without time for Etco2 accumulation and is consistent with evidence that patients
can develop respiratory arrest shortly after a nursing
visit.11
Improved OIRD detection on the general care
floor has important clinical implications, as shown
by a reduction of rapid response calls when using
unblinded continuous capnography.36 In this trial,
rescue, including rapid response team activation, and
hospitalization prolongation due to an adverse event
were 2.5 and 1.4 times higher, respectively, for patients
with respiratory depression. Consistent with previous
reports, patients with ≥1 respiratory depression episode experienced a 3-day longer hospital stay,9 equating to an economic burden of ≈$2000/d of inpatient
hospitalization and potential costs due to complications and escalation of care.37,38
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Overall, the number of opioid-induced respiratory complications requiring rescue was low. Ten
patients required rescue treatment during continuous
monitoring, and 11 patients needed rescue outside
of continuous monitoring. This frequency of rescue treatment is consistent with recent studies using
postoperative naloxone administration to define
OIRD18,39,40 and supports the hypothesis that OIRD
requiring rescue action occurs in ≈1 of 1000 general
care floor patients.18,39 Combined, the potential severity of respiratory complications (death, anoxic brain
injury) and the lack of OIRD detection by current
monitoring practices highlight the need for risk prediction and adequate monitoring. Implementation of
the PRODIGY score to determine the need for continuous monitoring may be a first step to reduce the
consequences of respiratory compromise.
One strength of the PRODIGY trial design was
inclusion of blinded, continuously monitored oximetry and capnography data and respiratory depression episode adjudication using an independent
clinical event committee, allowing us to observe the
true burden of respiratory depression. Furthermore,
www.anesthesia-analgesia.org 1021
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we included surgical and medical patients transferred
to a range of general care floors in Europe, the United
States, and Asia, making our findings generalizable.
Although it remains to be seen if universal continuous
monitoring will lead to a survival benefit for general
care floor patients, our data suggest that screening
with the easy-to-use PRODIGY score and the use of
continuous monitoring at least in patients with high
respiratory depression risk may prevent harm to
the individual patient. For example, a 72-year-old
male patient with chronic heart failure who is opioid naive is at a >2-fold risk of respiratory depression (PRODIGY score = 30; high risk) compared to a
67-year-old female patient with diabetes and chronic
kidney disease who has previously received opioids
(PRODIGY score = 8; intermediate risk) after a similar
surgical procedure, when both receive opioids on the
general care floor. Along with judicious use of opioids, this high-risk patient may benefit from continuous capnography and oximetry monitoring.
This work has some limitations. To evaluate OIRD
episodes, the clinical event committee required access
to opioid usage data, which could have influenced
episode adjudication. Thus, opioid naivety, but not
opioid doses and routes, was included in the model.
Second, although only one-fifth of all adjudicated
respiratory depression episodes were denoted as
having ≥1 artifact, capnography data were subject to
artifact and patient compliance. Finally, the trial was
internally validated but lacks external validation on
an independent cohort, primarily due to the nonavailability of a robust, continuously monitored patient
dataset from the general care floor. Future studies are
needed to validate the risk prediction tool.
Parenteral opioid use alone or in combination with
sedatives is strongly associated with cardiopulmonary
arrests on the general care floor.38 While judicious use
of these interventions is important, continuous monitoring for patients receiving opioids is also deficient.
A high incidence of respiratory depression episodes
was detected using continuous monitoring and these
may contribute to significant morbidity as seen by
the higher incidence of rapid response activation and
prolonged hospitalization. In the absence of interventional trials testing continuous monitoring and inpatient mortality, results from PRODIGY provide a tool
for respiratory depression risk assessment and suggest
that continuous monitoring with capnography and
oximetry of patients identified as high risk for respiratory depression may improve their safety when parenteral opioid analgesia cannot be avoided. E
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